KARAMFILOVA KATIA DIMITROVA,GUARNERI LUCIANO,LEONARDI AMEDEO,RIVA CARLO,GRAZIANI DAVIDE,MOTTA GIANNI,DE TOMA CARLO
申请号：
NZ60386811
公开号：
NZ603868A
申请日:
2011.07.08
申请国别(地区):
NZ
年份:
2014
代理人:
摘要：
ABSTRACT - 603868 The disclosure relates to diazaspiro compounds having the general formula (I) wherein X is O or S； R1 is C, N, O or S； R1a is CH, CH2, N or NH； R2 is a bond, CH or CH2； m is 1, 2 or 3； n is 1 or 2； when n is 2 or m is 2 or 3, the ring containing R1 may be fused with a benzene ring； each ----- (dashed line) represents a single or double bond provided that one double bond extends from the carbon atom to which R3-C=C- is bonded and that no ring carbon atom bears two double bonds； and R3, R4 and R5 represent a wide range of substituents as defined in the specification. These compounds are selective for the metabotropic mGlu5 receptor. They, their solvates, hydrates, enantiomers, diastereomers, N-oxides and pharmaceutically acceptable salts, and pharmaceutical compositions containing them, can be used to treat diseases or disorders of the lower urinary tract, especially neuromuscular dysfunctions of the lower urinary tract. They may also be useful for the treatment of migraine； for the treatment of gastroesophageal reflux disease (GERD)； for the treatment of anxiety disorder； for the treatment of abuse, substance dependence and substance withdrawal disorder； for the treatment of neuropathic pain disorder； and for the treatment of fragile X syndrome disorders.
